Pancreas, Liver and Shunt Procedures DRG Reimbursement

DRG 407 covers pancreas, liver, and shunt procedures without Complication or Comorbidity or Major Complication or Comorbidity; it defines a moderate-resource surgical cohort for inpatient payment. Proper assignment of this Diagnosis-Related Group matters because it determines the Medicare bundled payment level under the inpatient prospective payment system.

DRG 407 Overview

DRG 407 covers inpatient admissions for pancreas, liver, and shunt surgical procedures when no Complication or Comorbidity or Major Complication or Comorbidity is coded. This Diagnosis-Related Group groups moderate-complexity hepatobiliary and pancreatic resections, drainage procedures, and shunt operations that do not carry additional coded complications, which affects relative resource use. It matters for Medicare payment because classification into this Diagnosis-Related Group determines bundled payment weights and hospital reimbursement under the inpatient prospective payment system. Accurate coding of procedures and comorbidities is essential to ensure claims are assigned to the appropriate Diagnosis-Related Group for payment purposes.

DRG 407 Overview

Acute perioperative interventions: randomized or controlled studies testing surgical techniques, intraoperative management strategies, or immediate perioperative protocols for patients undergoing pancreas, liver, or portal-systemic shunt procedures without major complications. These trials enroll adult surgical patients scheduled for resections (partial pancreatectomy, hepatic segmentectomy) or shunt operations, and study outcomes such as intraoperative blood loss, rates of postoperative bile leak or pancreatic fistula, and short-term morbidity within the hospitalization. Findings are relevant to surgeons and hospital payers because optimized perioperative care can reduce length of stay, resource utilization, and complication-related costs for cases classified under DRG 407.
Comparative effectiveness studies of procedural approaches and device adjuncts: pragmatic trials or registries comparing minimally invasive (laparoscopic/robotic) versus open approaches, or evaluating use of specific hemostatic agents, stapling technologies, or anastomotic techniques in low-complexity pancreas and liver procedures. These studies typically involve patients without major comorbid complications and assess operative time, conversion rates, readmission, and short-term functional recovery metrics; they help determine which approaches offer equivalent or superior outcomes at similar or lower cost. Payers and hospital systems use this evidence to inform procedure selection, allocation of capital equipment, and perioperative care pathways for DRG 407 cases.
Post-discharge outcomes and resource utilization studies: observational cohort studies and quality-improvement research tracking 30–90 day readmissions, outpatient complication management, and patient-reported outcomes after uncomplicated pancreas, liver, or shunt procedures. These studies focus on transitions of care—identifying predictors of early readmission, outpatient interventions that prevent return to hospital, and the impact of follow-up models on functional recovery. Results are important for case management and reimbursement stakeholders because reducing post-discharge complications and readmissions improves value of care for DRG 407 hospitalizations and influences bundled payment and quality metrics.

Acute perioperative interventions: randomized or controlled studies testing surgical techniques, intraoperative management strategies, or immediate perioperative protocols for patients undergoing pancreas, liver, or portal-systemic shunt procedures without major complications. These trials enroll adult surgical patients scheduled for resections (partial pancreatectomy, hepatic segmentectomy) or shunt operations, and study outcomes such as intraoperative blood loss, rates of postoperative bile leak or pancreatic fistula, and short-term morbidity within the hospitalization. Findings are relevant to surgeons and hospital payers because optimized perioperative care can reduce length of stay, resource utilization, and complication-related costs for cases classified under DRG 407.
Comparative effectiveness studies of procedural approaches and device adjuncts: pragmatic trials or registries comparing minimally invasive (laparoscopic/robotic) versus open approaches, or evaluating use of specific hemostatic agents, stapling technologies, or anastomotic techniques in low-complexity pancreas and liver procedures. These studies typically involve patients without major comorbid complications and assess operative time, conversion rates, readmission, and short-term functional recovery metrics; they help determine which approaches offer equivalent or superior outcomes at similar or lower cost. Payers and hospital systems use this evidence to inform procedure selection, allocation of capital equipment, and perioperative care pathways for DRG 407 cases.
Post-discharge outcomes and resource utilization studies: observational cohort studies and quality-improvement research tracking 30–90 day readmissions, outpatient complication management, and patient-reported outcomes after uncomplicated pancreas, liver, or shunt procedures. These studies focus on transitions of care—identifying predictors of early readmission, outpatient interventions that prevent return to hospital, and the impact of follow-up models on functional recovery. Results are important for case management and reimbursement stakeholders because reducing post-discharge complications and readmissions improves value of care for DRG 407 hospitalizations and influences bundled payment and quality metrics.

OpenPayer

Pancreas, Liver and Shunt Procedures without CC/MCC: Inpatient Reimbursement Overview

Sign up for Pancreas, Liver and Shunt Procedures without CC/MCC: Inpatient Reimbursement Overview policy alerts

DRG 407 Overview

Catch payer policy changes before they impact reimbursement

Catch payer policy changes before they impact reimbursement

OpenPayer

Pancreas, Liver and Shunt Procedures without CC/MCC: Inpatient Reimbursement Overview

Sign up for Pancreas, Liver and Shunt Procedures without CC/MCC: Inpatient Reimbursement Overview policy alerts

DRG 407 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References